Skip to main content

Drug Interactions between lidocaine and linvoseltamab

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

lidocaine linvoseltamab

Applies to: lidocaine and linvoseltamab

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with linvoseltamab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of linvoseltamab treatment causes the transient release of cytokines that may suppress CYP450 isoenzymes; however, the potential for drug-drug interactions due to this effect has not been clinically evaluated. According to the manufacturer, increased exposure to CYP450 substrate(s) is more likely from the start of linvoseltamab therapy (including the initial step-up dosing schedule) through 14 days after the initial 200 mg dose, as well as during and following cytokine release syndrome. Increased exposure to the affected CYP450 substrate(s) may increase the risk of substrate-related adverse effects.

MANAGEMENT: Caution is advised when linvoseltamab is coadministered with drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic range, and where minimal changes to concentration may lead to significant adverse reactions (e.g. carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics). Clinical and/or laboratory monitoring are recommended, particularly at the initial phase of treatment with linvoseltamab as well as during and after cytokine release syndrome. Individual product labeling for the CYP450 substrate(s) should be consulted for specific dosage adjustment recommendations.

Drug and food/lifestyle interactions

Moderate

lidocaine food/lifestyle

Applies to: lidocaine

Grapefruit juice may increase the blood levels of lidocaine, which may increase the risk of side effects such as low blood pressure, slow heart rate, irregular heart rhythm, difficulty breathing and convulsions. Cigarette smoking may reduce the blood levels of lidocaine, which may make the medication less effective. It is best to avoid smoking during lidocaine therapy. Consuming cruciferous vegetables (e.G., broccoli, brussels sprouts) may also reduce the blood levels of lidocaine. Talk to a healthcare professional if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Moderate

lidocaine food/lifestyle

Applies to: lidocaine

Consumer information for this interaction is not currently available.

MONITOR: Smoking cessation may lead to elevated plasma concentrations and enhanced pharmacologic effects of drugs that are substrates of CYP450 1A2 (and possibly CYP450 1A1) and/or certain drugs with a narrow therapeutic index (e.g., flecainide, pentazocine). One proposed mechanism is related to the loss of CYP450 1A2 and 1A1 induction by polycyclic aromatic hydrocarbons in tobacco smoke; when smoking cessation agents are initiated and smoking stops, the metabolism of certain drugs may decrease leading to increased plasma concentrations. The mechanism by which smoking cessation affects narrow therapeutic index drugs that are not known substrates of CYP450 1A2 or 1A1 is unknown. The clinical significance of this interaction is unknown as clinical data are lacking.

MANAGEMENT: Until more information is available, caution is advisable if smoking cessation agents are used concomitantly with drugs that are substrates of CYP450 1A2 or 1A1 and/or those with a narrow therapeutic range. Patients receiving smoking cessation agents may require periodic dose adjustments and closer clinical and laboratory monitoring of medications that are substrates of CYP450 1A2 or 1A1.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer